YONSEI UNIVERSITY WONJU INDESTRY-ACADEMIC COOPERATION FOUNDATION
发明人:
JEONG, Yang Sik,정양식,KIM, Ki Woo,김기우,MO, Sang Hyun,모상현
申请号：
KRKR2015/006464
公开号：
WO2015/199454A1
申请日:
2015.06.25
申请国别(地区):
WO
年份:
2015
代理人:
摘要：
The present invention relates to a composition for preventing or treating a cancer resistant to a target anticancer drug, the composition including, as an active ingredient, a 3,4,5-trihydroxybenzoic acid (gallic acid) compound or a derivative thereof which specifically inhibits cancer cells that exhibit resistance to an anticancer drug targeting receptor tyrosine kinase. Since the 3,4,5-trihydroxybenzoic acid (gallic acid) compound or a derivative thereof specifically kills cancer cells that exhibit resistance to an anticancer drug targeting receptor tyrosine kinase, cancer diseases that are resistant to a receptor tyrosine kinase inhibitor such as gefitinib can be prevented or treated.La présente invention concerne une composition destinée à la prévention ou au traitement de cancers résistants à un médicament anticancéreux cible, la composition comprenant, en tant que principe actif, un composé dacide 3,4,5-trihydroxybenzoïque (acide gallique), ou un dérivé de celui-ci, qui inhibe spécifiquement les cellules cancéreuses qui présentent une résistance aux médicaments anticancéreux ciblant le récepteur de la tyrosine kinase. Lacide 3,4,5-trihydroxybenzoïque (acide gallique), ou un composé dérivé de celui-ci, détruisant spécifiquement les cellules cancéreuses qui présentent une résistance aux médicaments anticancéreux ciblant le récepteur de la tyrosine kinase, les maladies cancéreuses résistantes aux inhibiteurs du récepteur de la tyrosine kinase tel que le gefitinib peuvent être prévenues ou traitées.본 발명은 수용체 티로신 키나아제(receptor tyrosine kinase)를 표적으로 하는 항암제에 대하여 내성을 나타내는 암세포를 특이적으로 저해하는 3,4,5-트리하이드록시벤조산(Trihydroxybenzoic acid, gallic acid) 화합물 또는 이의 유도체를 유효성분으로 포함하는 표적 항암제에 대한 내성 암질환의 예방 또는 치료용 조성물에 관한 것으로서, 3,4,5-트리하이드록시벤조산(Trihydroxybenzoic acid, gallic acid) 화합물 또는 이의 유도체가 수용체 티로신 키나아제(receptor tyrosine kinase)를 표적으로 하는 항암제에 내성을 나타내는 암세포를 특이적으로 사멸시킴으로써 제피티닙(gefitinib) 등의 수용체 티로신 키나아제(receptor tyrosine kinase) 저해제에 내성 암질환을 예방 또는 치료할 수 있다.
